Lumosa Therapeutics Co (ROCO:6535) Float Percentage Of Total Shares Outstanding: 0.00% (As of Jul. 12, 2026)


ROCO:6535 Lumosa Therapeutics Co Ltd ROCO:6535
70 GF Score
Price NT$100.50
GF Value NT$131.19
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lumosa Therapeutics Co Float Percentage Of Total Shares Outstanding?

Lumosa Therapeutics Co ROCO:6535 70 Float Percentage Of Total Shares Outstanding is 0.00% as of Jul. 12, 2026. GuruFocus rates ROCO:6535 with a GF Score™ of 70/100 and a GF Value™ of NT$131.19 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Lumosa Therapeutics Co's float shares is 0.00 Mil. Lumosa Therapeutics Co's total shares outstanding is 167.49 Mil. Lumosa Therapeutics Co's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Lumosa Therapeutics Co's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Lumosa Therapeutics Co's Institutional Ownership is 3.46%.

ROCO:6535
70GF Score
Lumosa Therapeutics Co Ltd ROCO:6535
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lumosa Therapeutics Co Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Lumosa Therapeutics Co's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/167.49
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 0.00% mean?
Lumosa Therapeutics Co (ROCO:6535) has a Float Percentage Of Total Shares Outstanding of 0.00% as of Jul. 12, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Lumosa Therapeutics Co and its competitors.
Is Lumosa Therapeutics Co's Float Percentage Of Total Shares Outstanding too high?
Lumosa Therapeutics Co's current Float Percentage Of Total Shares Outstanding is 0.00%. Overall, Lumosa Therapeutics Co has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lumosa Therapeutics Co's Float Percentage Of Total Shares Outstanding compare to VRTX and REGN?
Lumosa Therapeutics Co's Float Percentage Of Total Shares Outstanding of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Lumosa Therapeutics Co and its competitors. Lumosa Therapeutics Co's current Float Percentage Of Total Shares Outstanding is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumosa Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, Lumosa Therapeutics Co (ROCO:6535) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$131.19, compared to a current price of NT$100.50 — trading 23.4% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 0.00%. Lumosa Therapeutics Co's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Lumosa Therapeutics Co (ROCO:6535), the current Float Percentage Of Total Shares Outstanding is 0.00% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?

Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued. The current stock price of NT$100.50 is trading 23.4% below its estimated GF Value™ of NT$131.19. GuruFocus considers Lumosa Therapeutics Co to be Modestly Undervalued.

Key valuation signals for ROCO:6535:

  • Float Percentage Of Total Shares Outstanding: 0.00%
  • GF Value™: NT$131.19 vs. price of NT$100.50 (23.4% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lumosa Therapeutics Co Business Description

Address Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
70GF Score

Get the complete analysis for ROCO:6535

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$100.50
Price
NT$131.19
GF Value